Inovio Pharmaceuticals Inc (NYSEMKT:INO) shows positive results in all its study


Dallas, Texas 08/02/2013 (Financialstrend) – Inovio Pharmaceuticals Inc (NYSEMKT:INO) the company which is showing positive results in all its study, recently announced that its Inovio’s hTERT   DNA cancer vaccine in the study with two animal models shown positive results  like broke the immune system’s , generating broad and robust  immune responses. Earlier its  PENNVAX -B preventive HIV DNA vaccine included two phase trials namely HVTN 070 and HVTN 080 which are discharged with DNA adjuvant with CELLECTRA electrooration delivery device of Inovio Pharmaceuticals Inc  has showed that responses in human for CD4  CD8 T-cell produced through the vaccine  was  durable and strong. This PENNVAX -B vaccine of Inovio Pharmaceuticals Inc achieved successful production of robust CD8 T-cell response which was before a great challenge for HIV researchers.

Inovio Pharmaceuticals Inc also got 100% successful result for the DNA vaccine which prevents animals from emerging flu named H7N9 virus. The study of DNA vaccine influenza study was done on mice samples and the final were when they were injected to a dosage of the vaccine with a lethal dosage of the H7N9 virus, all the samples were successfully sheltered from H7N9 flu virus which causes sickness and death. In addition to the protection from infection the vaccine also produced strong t-cell in the samples during the study.

Inovio Pharmaceuticals Inc (NYSEMKT:INO) closed at $1.95 per share on Thursday to make a gain of 11.43% over the previous close. The stock moved between $1.82 and $2.07 per share during the day. There are 179 million shares outstanding with institutional holding of 12%. The 52 week low is at $0.44 per share and 52 week high is at $2.20 per share. With $350.85 billion market capitalization there were 12.41 million shares of trading in the company’s stock on Thursday and the average volume is at 7.56 million shares per day.